Epithalamin raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-15 and is reviewed periodically as new material appears.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
The compound is generally presented as a synthetic fragment of epithalamin, a pineal gland extract investigated in the former Soviet Union from the 1970s onward. Vladimir Khavinson and colleagues in Saint Petersburg developed short peptides modelled on such extracts, and epitalon became the most widely cited of those sequences. Most primary reports appeared in Russian-language journals or in proceedings with limited international circulation. Independent replication in laboratories outside that network remains sparse, and much repeated secondary material traces back to a small number of originating groups.
Laboratory work has examined effects on telomerase activity in cultured cells, on melatonin rhythms in animals, and on markers of oxidative stress. Some experiments report measurable changes while others show none, and the reported findings rest largely on small studies. The absence of large independent trials means the generality of these results is unresolved rather than settled. Review articles occasionally apply the label geroprotector, a term that reflects a research hypothesis about ageing rather than an established clinical finding.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic tetrapeptide | Four amino acid residues |
| Residue sequence | Ala-Glu-Asp-Gly | Abbreviated AEDG |
| Approximate mass | 390.35 Da | Monoisotopic, free base form |
| Parent preparation | Epithalamin extract | Derived from pineal tissue |
| Common spelling variants | Epithalon, epithalone, AEDG | Affects literature retrieval |
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
Published evidence comes mainly from Russian-language journals and from a single research group, with small sample sizes and limited independent replication. A few laboratories outside that group have examined related peptides and reported weaker or absent telomerase effects, so the central claim is best described as contested rather than settled. Rodent studies report modest changes in some ageing markers and in survival, but designs vary and control conditions are often sparse. No large randomised trial in humans has been published, and long-term safety data in healthy populations are correspondingly thin.
Epitalon is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. It was designed at the St. Petersburg Institute of Bioregulation and Gerontology as a short, chemically defined analogue of epithalamin, a fraction obtained from bovine pineal tissue. Small peptide bioregulators of this type formed a long-running line of work there from the 1980s onward. Because the molecule is produced by solid-phase synthesis rather than extraction, its composition is exact and its purity can be measured directly.
== History == Potassium sulfate (K2SO4) has been known since early in the 14th century. It was studied by Glauber, Boyle, and Tachenius. In the 17th century, it was named arcanuni or sal duplicatum, as it was a combination of an acid salt with an alkaline salt. It was also known as vitriolic tartar and Glaser's salt or sal polychrestum Glaseri after the pharmaceutical chemist Christopher Glaser who prepared it and used medicinally. Known as arcanum duplicatum ("double secret") or panacea duplicata in pre-modern medicine, it was prepared from the residue (caput mortuum) left over from the production of aqua fortis (nitric acid, HNO3) from nitre (potassium nitrate, KNO3) and oil of vitriol (sulphuric acid, H2SO4) via Glauber's process:
A glycosidic bond is formed between the hemiacetal or hemiketal group of a saccharide (or a molecule derived from a saccharide) and the hydroxyl group of some compound such as an alcohol. A substance containing a glycosidic bond is a glycoside. The term 'glycoside' is now extended to also cover compounds with bonds formed between hemiacetal (or hemiketal) groups of sugars and several chemical groups other than hydroxyls, such as -SR (thioglycosides), -SeR (selenoglycosides), -NR1R2 (N-glycosides), or even -CR1R2R3 (C-glycosides). Particularly in naturally occurring glycosides, the compound ROH from which the carbohydrate residue has been removed is often termed the aglycone, and the carbohydrate residue itself is sometimes referred to as the 'glycone'.
=== Burn pits === A form of BO is starting to present in Iraq and Afghanistan veterans. It has been attributed to veterans being exposed to trash burn pits. Veterans present with shortness of breath and other asthma-like symptoms. The only way to diagnose this condition is by doing a lung biopsy as chest X-rays and CT scans come back as normal. The US government still denies that there is any correlation between burn pits and health problems, but has started an "Airborne Hazards and Open Burn Pit Registry" to begin tracking the health of veterans who were exposed to burn pits to see if there is a connection.
=== Research === The most commonly used application used for reporter genes has been for the identification of cis and trans acting elements. Through fusion to the promoter region of possible trans-cis acting elements, the change in fluorescence is measured and allows for tracking into transcriptional activity. This provides useful information into understanding the pathways these elements are involved in and its regulatory uses for cell development and growth. Immune responses are also a commonly used application of reporter genes and have benefited greatly through their use. They have allowed for further understanding in cell proliferation and differentiation into B-cells and T-cells during immune responses and have contributed to understanding activation through tracking cytokine signaling pathways. The development of reporter cell lines have also emerged with the discovery and use of reporter genes. The cell lines are labelled with reporter genes to allow for fluorescent detection to help with identification into proteins used in cellular pathways and identification into protein localization. This has allowed for a simple way to study protein progression that doesn't permit further experimentation for introduction and fusion of a reporter gene as the reporter gene is already present in the cell line. A more complex use of reporter genes on a large scale is in two-hybrid screening, which aims to identify proteins that natively interact with one another in vivo.
Sources: en.wikipedia.org
N terminus-Met-Gln-Pro-Arg-Arg-Gln-Arg-Leu-Pro-Ala-Pro-Trp-Ser-Gly-Pro-Arg-Gly-Pro-Arg-Pro-Thr-Ala-Pro-Leu-Leu-Ala-Leu-Leu-Leu-Leu-Leu-Ala-Pro-Val-Ala-Ala-Pro-Ala-Gly-Ser-Gly-Gly-Pro-Asp-Asp-Pro-Gly-Gln-Pro-Gln-Asp-Ala-Gly-Val-Pro-Arg-Arg-Leu-Leu-Gln-Gln-Lys-Ala-Arg-Ala-Ala-Leu-His-Phe-Phe-Asn-Phe-Arg-Ser-Gly-Ser-Pro-Ser-Ala-Leu-Arg-Val-Leu-Ala-Glu-Val-Gln-Glu-Gly-Arg-Ala-Trp-Ile-Asn-Pro-Lys-Glu-Gly-Cys-Lys-Val-His-Val-Val-Phe-Ser-Thr-Glu-Arg-Tyr-Asn-Pro-Glu-Ser-Leu-Leu-Gln-Glu-Gly-Glu-Gly-Arg-Leu-Gly-Lys-Cys-Ser-Ala-Arg-Val-Phe-Phe-Lys-Asn-Gln-Lys-Pro-Arg-Pro-Thr-Ile-Asn-Val-Thr-Cys-Thr-Arg-Leu-Ile-Glu-Lys-Lys-Lys-Arg-Gln-Gln-Glu-Asp-Tyr-Leu-Leu-Tyr-Lys-Gln-Met-Lys-Gln-Leu-Lys-Asn-Pro-Leu-Glu-Ile-Val-Ser-Ile-Pro-Asp-Asn-His-Gly-His-Ile-Asp-Pro-Ser-Leu-Arg-Leu-Ile-Trp-Asp-Leu-Ala-Phe-Leu-Gly-Ser-Ser-Tyr-Val-Met-Trp-Glu-Met-Thr-Thr-Gln-Val-Ser-His-Tyr-Tyr-Leu-Ala-Gln-Leu-Thr-Ser-Val-Arg-Gln-Trp-Val-Arg-Lys-Thr-C terminus.
=== MP for Henley: 1974–2001 === Heseltine, by now a junior minister in the Heath government, was now forced to apply for a new candidacy, often in competition with other sitting Conservative MPs whose seats were also due for abolition. He applied for Mid Sussex in competition with Ian Gilmour, but they lost to Tim Renton. He also applied for Mid-Oxfordshire but lost to Douglas Hurd. In 1972 Edward Heath attempted to persuade Heseltine, a strong supporter of his, to challenge Powellite MP Ronald Bell for the Conservative nomination for the new seat of Beaconsfield. Heseltine wrote that he was "tempted" to enter the lists at Beaconsfield, but did not actually do so. Crick writes that he reached the final shortlist of four against Bell, before being "apparently persuaded" to withdraw. Bell's campaign within the local Conservative ranks was masterminded by Hugh Simmonds, chairman of the Young Conservatives, and he narrowly won. Heseltine was one of 180 applicants for the safe Conservative seat of Henley (the constituency association of which was known as North Oxfordshire), whose MP John Hay was stepping down. He reached the final shortlist of three along with two other sitting MPs, William Shelton and Norman Fowler, and in September 1972 was selected as candidate with a clear majority at the first ballot. Part of the reason was that the Association wanted a wealthy MP who would not be distracted by the need to earn money in business as Hay had been. He maintained a constituency home in Crocker End, near Nettlebed, and still maintained a London home at Wilton Crescent.
A catch bond is a type of noncovalent bond whose dissociation lifetime increases with tensile force applied to the bond. Normally, bond lifetimes are expected to diminish with force. In the case of catch bonds, the lifetime of the bond actually increases up to a maximum before it decreases like in a normal bond. Catch bonds work in a way that is conceptually similar to that of a Chinese finger trap. While catch bonds are strengthened by an increase in force, the force increase is not necessary for the bond to work. Catch bonds were suspected for many years to play a role in the rolling of leukocytes, being strong enough to roll in presence of high forces caused by high shear stresses, while avoiding getting stuck in capillaries where the fluid flow, and therefore shear stress, is low. The existence of catch bonds was debated for many years until strong evidence of their existence was found in bacteria. Definite proof of their existence came shortly thereafter in leukocytes.
=== Reduction of endogenous quinones === NQO1 plays a role in ubiquinone and vitamin E quinone metabolism. These quinones protect cellular membranes from peroxidative injury in their reduced state. Furthermore, reduced forms of ubiquinone and vitamin E quinone have been shown to possess antioxidant properties that are superior to their non-reduced forms.
=== Other carbon-14 sources === Carbon-14 can also be produced by other neutron reactions, including in particular 13C(n,γ)14C and 17O(n,α)14C with thermal neutrons, and 15N(n,d)14C and 16O(n,3He)14C with fast neutrons. The most notable routes for 14C production by thermal neutron irradiation of targets (e.g., in a nuclear reactor) are summarized in the table. Another source of carbon-14 is cluster decay branches from traces of naturally occurring isotopes of radium, though this decay mode has a branching ratio on the order of 10−8 relative to alpha decay, so radiogenic carbon-14 is extremely rare.
Sources: en.wikipedia.org
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer that accounts for ten to fifteen percent of all breast cancer cases. Chemotherapy is the only viable current treatment for TNBC because the loss of target receptors inherent to the disease causes cancer cells to resist therapeutic pharmaceuticals. The three-way junction in the φ29 DNA packaging motor can help sensitize TNBC cells to chemotherapy using a siRNA drug delivery mechanism to inhibit TNBC growth and volume. This treatment can also be combined with anti-cancer drugs like Doxorubicin to enhance therapeutic effects. Bacteriophage Bacteriophage pRNA φ29 DNA polymerase
In 1976, Guillaume played Nathan Detroit in the Broadway revival of Guys and Dolls and was nominated for a Tony Award. In 1990, Guillaume was cast in the Los Angeles production of The Phantom of the Opera, replacing Michael Crawford in the title role. Guillaume was the first Black actor to portray the character.
14 December Scientists report that genes inherited by modern humans from Neanderthals and Denisovans may biologically influence the daily routine of modern humans, specifically their chronotype. Astronomers report the first time discovery, in the plumes of Enceladus, moon of the planet Saturn, of hydrogen cyanide, a possible chemical essential for life as we know it, as well as other organic molecules, some of which are yet to be better identified and understood. According to the researchers, "these [newly discovered] compounds could potentially support extant microbial communities or drive complex organic synthesis leading to the origin of life." 15 December – Google DeepMind claims to have made the first ever scientific discovery with an AI chatbot by building a fact-checker to filter out useless outputs, leaving useful solutions to mathematical or computing problems. 19 December – COVID-19: The World Health Organization designates JN.1, part of the BA.2.86 SARS-CoV-2 lineage, as its own variant of interest. This follows a recent, rapid rise in case numbers around the world. 20 December A new class of antibiotic candidates, able to kill methicillin-resistant Staphylococcus aureus (MRSA) is identified using deep learning. An experimental study reports online search to evaluate the truthfulness of false news articles increases the probability of believing them, especially for those for whom search engines return lower-quality information. It suggests media literacy programs with tested strategies and solutions for identified search engines issues are needed.
5-Hydroxytryptophan (5-HTP), used medically as oxitriptan, is a naturally occurring amino acid and chemical precursor as well as a metabolic intermediate in the biosynthesis of the neurotransmitter serotonin. 5-HTP can be manufactured and used as a drug and supplement with the INNTooltip International Nonproprietary Name oxitriptan. Brand names include Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum. As a drug, it is used in the treatment of depression and for certain other indications.
== Uses == Patulin was originally used as an antibiotic against Gram-positive and Gram-negative bacteria, but after several toxicity reports, it is no longer used for that purpose. Isolated by Nancy Atkinson in 1943, it was specifically trialed to be used against the common cold. Patulin is used as a potassium-uptake inhibitor in laboratory applications. Kashif Jilani and co-workers reported that patulin stimulates suicidal erythrocyte death under physiological concentrations.
Sources: en.wikipedia.org
It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.
No. Epithalamin is a heterogeneous extract containing many peptides, while epitalon is a single synthesised tetrapeptide. Publications sometimes treat findings from the two as equivalent, which is a common source of confusion. Their compositions differ and they are not interchangeable in analytical terms.
Most published work uses cell cultures or rodents because those models are faster and less costly to run. The few human trials that have been reported are small, and several lack control groups or blinding. This restricts what can reasonably be concluded about effects in people.
It is a four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine. The chain is unmodified and contains only standard proteinogenic residues, which makes it straightforward to produce by solid-phase synthesis and to characterise by standard peptide methods.